AptarGroup Inc. has announced a collaboration with CastleVax for the Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. Aptar’s innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being used in the trial to assess the safety, tolerability, and immune responses of the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine. This partnership highlights Aptar’s expertise in advanced drug delivery technologies and its role in supporting the development and accelerated market entry of novel immunization strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113832919) on January 13, 2026, and is solely responsible for the information contained therein.